Pleno’s Hypercoding technology has wide applicability across many different known-content applications. 

RAPTOR Delivers Compelling Performance Across Many Applications

In all known-content applications, including oncology, NIPT, pharmacogenomics, agrigenomics, and proteomics, Pleno has demonstrated the ability to detect all relevant biomarkers (including SNVs, Small and Large Indels, Direct DNA Capture, CNVs, Methylation, Fusions, Proteins, and even Pseudogenes).

Across the board, Pleno has shown it can successfully reduce costs (both the upfront capital equipment, and downstream per sample costs), improve TAT and reduce operational complexity, leading to best-in-class total cost of operation.

Application Spotlight


Pharmacogenomics (or PGx) is the study of how genes affect an individual’s response to drugs. It involves analyzing a patient’s genetic makeup to predict drug efficacy and risk of adverse reactions.

The goal of PGx is to develop rational means to optimize drug therapy by selecting medications and doses tailored to an individual’s genes. Most drugs are metabolized by enzymes encoded by specific genes.

Polymorphisms in these drug-metabolizing enzymes can affect a drug’s efficacy and toxicity. For example, variants in CYP2D6, CYP2C19, and CYP2C9 can alter metabolism of many commonly prescribed drugs. PGx tests can identify these variants to guide drug choice and dosing.

The clinical implementation of PGx has the potential to improve patient care by maximizing therapeutic benefits while minimizing risks. This emerging field is making precision medicine a reality by enabling physicians to prescribe drugs focused on a patient’s specific genetic profile.

PGx promises to revolutionize the practice of medicine and clinical drug development through genomic-based personalized medicine.

Read Our Pharmacogenomics Application Note

Take a look at the result data we have generated in our Pleno Apps Lab. Click on the button below to request access to this 4-page summary PDF.

Application Spotlight


Targeted proteomics utilizes oligo-conjugated antibodies to selectively isolate and quantify proteins of interest from complex biological samples. Antibodies conjugated to oligonucleotides can capture target proteins while retaining a unique molecular identifier for each protein.

The antibody-oligonucleotide complexes are then isolated and the oligos are purified. This enables multiplexed measurement of the proteins by readout technologies like microarrays, next-generation sequencing and Pleno’s RAPTOR Hypercoding Platform.

Compared to global discovery proteomics, the antibody-oligonucleotide method provides increased specificity, scalability, and throughput for measuring defined protein panels. Key applications include biomarker validation, clinical testing, and cell signaling analysis. The assay specificity arises from the antibodies while the oligos allow highly multiplexed measurements.

Continued improvements in antibody selectivity and advances in readout platforms like Pleno’s RAPTOR are expanding this technology for large-scale verification of protein biomarkers in biomedical research and diagnostics.

Read Our Proteomics Application Note

Take a look at the result data we have generated in our Pleno Apps Lab. Click on the button below to request access to this 4-page summary PDF.